Featured Publications
Generalizing the per-protocol treatment effect: The case of ACTG A5095
Lu H, Cole S, Hall H, Schisterman E, Breger T, Edwards J, Westreich D. Generalizing the per-protocol treatment effect: The case of ACTG A5095. Clinical Trials 2018, 16: 52-62. PMID: 30326736, PMCID: PMC6693502, DOI: 10.1177/1740774518806311.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Retroviral AgentsClinical ProtocolsFemaleHIV InfectionsHumansIntention to Treat AnalysisMaleMiddle AgedSustained Virologic ResponseViral LoadConceptsFour-drug antiretroviral regimenThree-drug regimenConventional intentionAntiretroviral regimenVirologic failureTreat comparisonProtocol deviationsRisk differenceTarget populationTreatment assignmentThree-drug armInverse probability weightsACTG A5095Protocol effectUS HIVHazard ratioRandomized trialsInverse oddsTreatment protocolRegimenUS individualsHIVProtocol estimatesTrialsProtocol analysis
2020
What we talk about when we talk about durable viral suppression.
Diepstra K, Lu H, McManus K, Rogawski McQuade E, Rhodes A, Westreich D. What we talk about when we talk about durable viral suppression. AIDS 2020, 34: 1683-1686. PMID: 32732633, PMCID: PMC7845768, DOI: 10.1097/qad.0000000000002612.Peer-Reviewed Original Research